DreaMS
What it found
We found no results in the registry or in papers.
This trial finished 14 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- ONO-4641
Placebo or sham
- ONO-4641 placebo
What it measured
Main measures
Total number of T-1-weighted Gd-enhanced lesions obtained with MRI at 4-week intervals for 26 weeks.
26 weeks
MRI lesionsThe primary endpoint will be the cumulative number of T1 weighted gadolinium (Gd)-enhanced lesions obtained with MRI at Weeks 10, 14, 18, 22 and 26. Patients who complete the treatment period or who discontinued during the treatment period and do not proceed to the extension study will enter the 4-week Follow-up Period.
MRI lesions
Other measures (1)
Total volume of Gd-enhanced lesions
26 weeks
MRI lesions
Who could take part
Relapsing MS · 18 to 55
Inclusion Criteria: * Adult male or female aged 18-55 years inclusive at screening * Patients who have a definite diagnosis of relapsing-remitting Multiple Sclerosis Exclusion Criteria: * Multiple Sclerosis course other than relapsing-remitting multiple sclerosis * History of malignancy * History of clinically significant chronic disease of the immune system (other than Multiple Sclerosis) * Inability to undergo Gd-enhanced MRI scans * Diagnosis of diabetes mellitus (type I or type II)
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.
Papers
Loading reviews and guidelines…
Linked trials
Extended by
DreaMSPhase 2 · Stopped early
Links found where a registry record names another trial's registry number.
History
Started
Mar 2010
Main results due
Dec 2011
Finished
Dec 2011
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error